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 Abstract: 
               The basic aim is formulate, evaluate and optimize the Metformin Hydrochloride 
immediate release tablet by wet granulation technique. The Metformin is used as an ant diabetic 
drug. In order to obtain the best, nine different formulations were developed. Different binders, 
disintegrants and lubricants taken as variables. Pre compression parameters like Bulk density, 
True density, Angle of repose indicate all the formulations are showing good flow properties. 
The granules are compressed and tablets are evaluated for post compression parameters weight 
variation, Hardness, Friability, Disintegration and Dissolution parameters. Among all the 
formulations F9 is showing the release profile similar to the innovator. The compressed tablets 
was packed in blisters and subjected to stability studies at 400C and 75% RH, 250C and 60%RH. 
Samples were analyzed at regular intervals as mentioned in stability protocol. It may be 
concluded that Metformin tablet prepared as immediate release formulation compared to 
conventional formulations. 
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1. INTRODUCTION 
  
                                                Oral drug delivery is the fastest and more preferred route for 
the drug administration is also the largest and oldest segment of the total drug delivery 
market. Various types of drug delivery systems are available to get better therapeutic action 
of drug, out of which immediate release drug delivery system is gaining more importance 
because of their wide advantages over others like ease of administration , convenience and 
noninvasiveness.(1) 
                                                Metformin was discovered in 1922.Study in humans began in 
1950s by French physician Jean Sterne. It was introduced in France in 1957 and the United 
States in 1995.It is on the World Health Organization's List of Essential Medicines, the most 
important medications needed in a basic health system. Metformin is believed to be the most 
widely used medication for diabetes which is taken by mouth (2) .Metformin hydrochloride 
(MH) is an oral hypoglycemic drug that has been used for the management of the non-
insulin-dependent diabetes mellitus. It is taken in tablets of 500 and 850mg, with low and the 
incomplete absorption by the gastrointestinal tract, the usual dose being 2g/day and the 
maximum dose 3g/day.  
 
1.1 IMMEDIATE RELEASE DRUG DELIVERY SYSTEM (3,5,6) 
                                                     Immediate release tablet dosage forms are those which 
dissolved and get rapidly disintegrate to release the medicaments to produce rapid action. It 
should dissolve or disintegrate in the stomach within a short period of time. It should exhibit 
low sensitivity to environmental conditions as humidity and the temperature. Be 
manufactured using conventional processing and packaging equipment at low cost. It should 
not leave minimal or no residue in the mouth after oral administration. It produces rapid 
dissolution and absorption of drug, which may produce rapid onset of action. Immediate 
release may be provided for by way of an appropriate pharmaceutically acceptable diluents or 
carriers are does not prolong ,to an appreciable extend, the rate of drug release and/or 
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absorption .This term excludes formulations which are adapted to provide for “modified”, 
“controlled”, “sustained”, “prolonged”, “extended”, or “delayed” release of drugs. 
   For immediate release tablet disintegrates play a major role in 
ensuring that tablet matrix break up on the contact with the fluid present in the stomach to 
allow the release of active component which then become available in whole or in part, for 
absorption from gastrointestinal tract. 
 
Criteria for immediate release drug delivery system (4):                                                                                                                              
Immediate release dosage form should – 
 In the case of the solid dosage forms it should be dissolve and disintegrate in the 
stomach within the short period of the time. 
 In the case of the liquid dosage forms it should compatible with taste masking. 
 It should not leave minimal or no residue in the mouth after the oral 
administration. 
 It should have pleasing mouth feel. 
 It should be portable without fragility concern. 
 It act rapid dissolution and absorption of drug, which may produce the rapid 
onset of action. 
 Be manufactured by using the conventional processing and packaging 
equipment at low cost. 
 It exhibit low sensitivity to environmental conditions like humidity and 
temperature. 
 
The merits of immediate release drug delivery system (4, 15):  
 It allows the high drug loading. 
 Improved compliance. 
 Improved bioavailability, solubility. 
 It ability to provide advantage of liquid medication in the form of the solid 
dispersion. 
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 Immediate release drug delivery system will produce decreased disintegration 
and the dissolution times. 
 It improved the solubility of pharmaceutical preparations. 
 Immediate release drug delivery system allow the high drug loading 
 It effective on cost. 
 Amenable and adaptable to existing processing and the packaging machinery. 
 The ability to provide advantage of liquid medication in the form of solid 
preparations. 
 
1.2 ANTIDIABETICS (2,16,13,14) 
                      Drugs used in diabetes treat diabetes mellitus by lowering 
glucose levels in the blood. With the exceptions of insulin, exenatide, liraglutide and 
pramlintide, all the administered orally and are thus also called oral hypoglycemic agents or 
oral anti hyperglycemic agents. There are different classes of anti diabetic drugs, and there 
are different classes of anti-diabetic drugs, and their selection depends on the nature of the 
diabetes, age and situations of the person, as well as other factors. The Diabetes Mellitus 
describes a metabolic disorder of multiple aetiology. The effect of Diabetes Mellitus includes 
dysfunction, failure and long term damage of various organs. In most severe form of DM 
nonketotic hyperosmolar state may develop. 
 
Diabetes mellitus type1                 
                                                It is a disease caused by the lack of insulin .it comes about due 
to the loss of pancreatic function. The loss of pancreatic function may be due to disease or 
injury to the pancreas which ultimately leads to loss of optimum glycaemic control. Thus, 
insulin needs to be injected subcutaneously twice daily to compensate for the needs of the 
body (also referred as insulin-dependent-diabetes mellitus, and juvenile diabetes) 
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Diabetes mellitus type 2 
                                                There is a decrease in the body’s secretion and sensitivity to 
insulin, which usually caused by obesity.   It is a disease of insulin resistance by cells. Type 2 
diabetes mellitus is the most common type of diabetes. Treatments include  
1) Agents that increase the amount of insulin secreted by the pancreas. 
2) Agents that increase the sensitivity of target organs to insulin.  
3) Agents that decrease the rate at which glucose is absorbed from the 
gastrointestinal tract. 
 
Several groups of drugs , mostly given by mouth , are effective In type 2 ,often in 
combination .The therapeutic combination in type 2 may include insulin, not necessarily 
because oral agent have failed completely, but in search of a desired combination of effect. 
The great advantage of injected insulin in type 2 is that a well-educated patient can adjust the 
doses. When blood glucose levels measured by the patient, usually with a simple meter, as 
needed by the measured amount of sugar in the blood. 
                                                    Non insulin-dependent diabetes mellitus, maturity onset 
diabetes mellitus: There is no loss or moderate reduction in β cell mass; insulin in circulation 
is low ,normal or even high, no anti β cell antibody is demonstrable; has a high degree of 
genetic predisposition; generally has a late onset(past middle age).Over 90% cases are 
type2DM.Causes may be: 
 
 Abnormality in gluco-receptor of β cells so that they respond at 
higher glucose concentration or relative β cell deficiency. 
 Reduced sensitivity of peripheral tissue to insulin: reduction in 
number of insulin receptors ‘down regulation’ of insulin receptors. 
 Excess of hyperglycemic hormone, causes relative insulin deficiency  
the β cells lag behind. 
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1.3 ORAL HYPOGLYCAEMIC DRUGS (17,18) 
 More than 95% of Type2 Diabetic patients in our country, and it 
have already reached in epidemic proportions, mainly in Urab India. Possibly India shall have 
about 57.2 million diabetics by the year of 2015. These drugs lower blood glucose levels and 
are effective orally. The chief drawback of insulin is –it must be given by injection. Orally 
active drugs have always been searched. 
 SULFONYLUREAS 
 First generation 
 Tolbutamide 
 Chlorpropamide 
 
 Second generation 
 Glibenclamide 
 Glipizide 
 Gliclazide 
 Glimepride 
 
 BIGUANIDES 
 Metformine 
               PHENYL ALANINE ANALOGUES 
 Repaglinide 
 Nateglinide 
 
  THIAZOLIDNEDIONES 
 Rosiglitazone 
 Pioglitazone 
 α GLUCOIDASE INHIBITORS 
 Acrbose 
 Miglitol  
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1.5 TABLETS (7,8,9,15,16) 
 Tablets are solid dosage forms, flat or biconvex in shape, 
prepared may be swallowed or being chewed. Some types of tablets are in dissolved or 
dispersed in water. And also implants and passerines also be presented in form of tablets. 
Tablets may vary in size, shape, and weight depending on the medical substances and mode 
of administration. The manufacture of oral dosage form is a complex multistage process. The 
starting material changes their physical characteristics. Traditionally dry granulation and wet 
granulation are used. 
 
Advantages of the tablets 
 Accuracy of dose can be maintained since tablet is a solid dosage form. 
 Ease of handling and the easy of packing over the other dosage forms. 
 Identification of the product is easy and marking done with the help of 
grooved punches and printing with the edible ink. 
 Compare to parental dosage forms, not required for other persons like doctors 
or nurse -that is self administration is possible. 
 In comparison with capsules, tablets are the more water proof. 
 Different types of the solid dosage forms are available like floating, buccal, 
colon targeting, effervescent, chewable, soluble etc. 
 Emergency supplies  can be carried by patients, 
 Easy to transport in bulk. 
 Longer expiry period and the minimum microbial spillage owing to lower 
moisture content. 
 Organoleptic properties can be improved by the coating method. 
 The solid dosage forms are not a sterile dosage forms, stringent environmental 
conditions are not required in the tablet department. 
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Disadvantages of tablet 
 It produce slow onset of action as compared to liquid orals, capsules and 
parental. 
 Cannot swallow tablet who patients undergoing radiotherapy. 
 Difficult to convert high dose poorly compressible API in to tablet of suitable 
size for human use 
 Tablet dosage forms are difficult to formulate with poor wet ability, slow 
dissolution in to a tablet. 
 
1.5.1 TYPES OF TABLETS (8,9,10) 
 Different types of tablets are developed. With advancement in 
technology, modification in tablets to achieve better bioavailability , newer and efficient 
dosage forms are being developed, 
Tablets here are classified by their route of administration.                                                          
A. Oral tablets for ingestion.                                                                                                                                                                                                                                  
 This class of formulation is the most popular worldwide and the 
major attention of the researcher is towards this direction. These tablet dosage forms are 
swallowed along with sufficient quantity of water exception is chewable tablet. Now 90% of 
the solid dosage forms are ingested orally. 
B. Multiple compressed tablets 
                                    
 Layered tablet 
 Floating tablet 
 Chewable tablet 
 Compression coated tablet 
 Delayed action tablet 
 Colon targeting tablet 
 Dispersible tablet 
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C. Tablets used in oral cavity 
                           
                                         Tablet under this category avoid the first pass metabolism, 
decomposition in gastric environment, nausea tic sensation and gives rapid onset of 
action. These groups are aimed to release API in oral cavity or to provide local action on 
this region. 
 
 Mouth dissolved tablet 
 Lozenges and troches 
 Buccal tablet dental cones 
 
D. Tablets administered by other routes 
 
                               These are administered by other route except oral cavity and so 
drugs are avoided from passing through gastro intestinal tract. These types of the tablets 
may be directly placed below the skin or inserted in other body cavities to be absorbed to 
systemic circulation from the site of application. 
 
 Vaginal tablet 
 Implants 
 
E. Tablets used to prepare solution 
 These groups of tablets are required to dissolve in water or 
other solvents before administration. This solution may be for parentral applications or 
ingestion or topical use depends upon type of medicament used. 
 Effervescent tablet 
 Hypodermic tablet                                                                                                                             
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1.6 ROLE OF EXCIPIENTS IN SOLID DOSAGE FORM (11,12,4) 
                                         The excipients are balance the properties of the immediate 
release dosage forms. The excipients are very important in understanding the chemistry of the 
interactions with the actives. Excipients are general and can use for a broad range of 
activities. 
 
A. Diluents or fillers 
 Diluents or fillers are added where the quantity of active 
ingredient is small or difficult to compress. 
Eg; lactose, mannitol 
 
B. Binders 
          
                              These are the adhesives that are added to the tablet formulation. 
The role of binders is to provide the cohesiveness essential for the bonding of the solid 
particles under compaction to form a tablet in a wet granulation process, binderes promote 
size enlargement to provide granules, and they improve flow ability. 
Eg; starch, gelatin, tragacanth 
 
C. Disintegrants 
                                      The major role of this is helping the tablet break up after the 
administration of tablet. The super disintegrants is an excipient which is added to a tablet or 
capsule to break up the compactable mass .it effective in the lower concentration and less 
effective on compressibility and flow ability. 
Eg; sodium starch glycolate, cross carmellose 
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D. Lubricants 
 It prevents powders from sticking to the metal component of 
the tablet press and the tablet press toolings. It also helpful for removal of grittiness and also 
assist the drug transport mechanism from mouth to down the stomach. 
Eg; talc, aerosol 
 
E. Glidants 
                                                Glidants are the agents that act as a reducing inter particular 
friction 
Eg; magnesium state 
 
F. Adsorbents 
                                         These are the substances included in the formulations that are 
capable of holding fluid in an apparently dry state. Fluid extracts or oil soluble drugs can be 
mixed with adsorbents then granulated and compressed in to tablets. 
Eg; fumed silica, microcrystalline cellulose, magnesium carbonate 
 
G. Colorants 
                                              Colorants are added for the product identification. 
 
1.7TABLET MANUFACTURING PROCESS (8,9,10,30) 
 In the tablet manufacturing process the granulation is the 
important process. The particles given in granulation process will improve the content 
uniformity, flow and compression characteristics, reduce segregation and eliminate excessive 
amount of particles. The results improve the yield, reduced the tablet defects. The objective 
of the process is to produce a quality tablet. 
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Table no: 1 Steps involved in the tablet manufacturing process. 
 
 
S.NO PROCESSING 
STEPS 
DIRECT 
COMPRESSION 
WET 
GRANULATION 
DRY 
 GRANULATION 
1 RAW 
MATERIALS 
YES YES YES 
2 WEIGHING YES YES YES 
3 SCREENING YES YES YES 
4 MIXING YES YES YES 
5 COMPRESS YES NO  YES 
6 WET MASS NO  YES NO 
7 MILLING NO  NO YES 
8 DRYING NO YES NO 
9 SHIFTING NO YES YES 
10 MIXING NO YES YES 
11 COMPRESSION NO  YES YES 
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1.8 STABILITY STUDY AS PER ICH GUIDELINES (35,36) 
                                    Stability is defined as the capacity of the drug product to remain the 
established specification to maintain its strength, identity, purity, throughout the expiration 
dating period.  
                                The objective of the stability study determine the shelf life, the shelf life 
means the time period of storage at a specific condition within which the drug product still 
meets its established specification. Stability is the essential part for the quality, safety and 
efficacy of product. This is not of sufficient stability results in changes in physical as well as 
chemical characteristics. 
                              The chemical stability of drug is of great importance since it becomes less 
effective as it undergoes degradation. Microbiological instability of a sterile drug product 
could also be hazardous. Stability valuation of drug substance is the key to drug quality as it 
determines the efficacy of dosage form. In fact stability testing issues are responsible for 
number of audit findings by the regulatory agencies. Stability testing provides evidence that 
the quality of drug substance change with time under the influence of various environmental 
conditions such as the humidity, temperature etc. Stability studies consist of the series of test 
in order to maintain a assurance of stability of drug product, involved drug product packed in 
specified packaging material and stored in definite storage conditions within the determined 
time period.  
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 AIM OF STUDY 
     
                                    Development and evaluation of Metformine hydrochloride IP 
500mg tablets by using nine optimized formulations. 
 
 OBJECTIVE OF STUDY 
               
 Carrying out literature survey of the drug molecules  
 Formulation of the tablets using different trails 
 Analyzing the trial samples  
 Optimizing the final formula 
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3. PLAN OF WORK 
 Development of final formula 
 
 Literature collection for trial product 
 
 Pre formulation studies 
 
 Formulation of trail products 
 
 Dissolution studies of formulations  
 
 Finalization of quantitative formula 
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 Adimoolam Senthil, Prasanthi sri et al(2013)41 - Metformin HCl is an oral anti-
hyperglycemic drug used for the treatment of non-insulin dependent diabetes mellitus. 
Metformin hydrochloride is a highly water soluble, hygroscopic and odorless. 
Consequently, there is a need to provide a free-flowing and cohesive Metformin 
hydrochloride capable of being directly compressed into the tablets with an acceptable 
in vitro dissolution profile. Different types of directly compressible excipients 
(disintegrant, diluents, binder) were evaluated to find the maximum amount of 
Metformin HCl to be loaded in tablet for direct compression. An approach to further 
increase Metformin hydrochloride was designed by employing recrystallization 
technique such as anti-solvent method. Metformin hydrochloride was recrystallized in 
the presence of different concentration of PVP K30 for different intervals of 
recrystallization time. A 32 full factorial design was employed to get optimum 
processing conditions. The recrystallized Metformin hydrochloride was explored for 
preparation of the sustained release tablet by using the hydroxypropylmethyl cellulose 
K15 M.Weibull model is adopted for release profile. 
 
 Dr K.L.Senthilkumar,R.P Ehizilmuthu et al(2011)42 - The Study aim to development 
and evaluation of Metformin sustained release tablets using different polymers as 
release retarding agent. It is studied that formulation of sustained release tablet of 
Metformin containing 13 % HPMC K100 with binder PVP K30 i.e. optimized 
formulation of sustained release tablets for 10 hour release as it fulfills all the 
requirements for sustained release tablet. The sustained release tablets of Metformin 
hydrochloride prepared by wet granulation and direct compression method. The 
granules for the matrix tablet were prepared according to the angle of repose, total 
drug content and bulk density. The different in amount of polymer was largely 
dependent the viscosity grade, gel swelling and diffusion behavior of HPMC. 
 
 Rikin Patel, Nidhi Shah et al(2011)43- Quality cannot be assured by in-process and 
finished product testing. This study about the process validation of Metformine 
hydrochloride and Glimipride extended release bilayered tablet. The quality should be 
built into the various stages of process of manufacturing steps. To obtain the quality 
specifications in finished product, various manufacturing processes with various 
manufacturing steps including critical process parameters should be controlled. The 
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critical process parameters can be evaluated by performing various tests at different 
stages. In this study taken three process validation batches of same size, method, 
equipment and validation criteria were taken. The critical parameters involved in the 
process are sifting, granulation, pre compression and compressions were evaluated. 
Different steps of manufacturing procedures were evaluated for in the process of pre 
compression and post compression steps; acceptable moisture content after drying, 
acceptable particle size distribution, blend uniformity, bulk density,  weight variation, 
thickness, hardness, %friability, dissolution, disintegration after compression. The 
results of these parameters indicated that this process validation data provides high 
degree of assurance that manufacturing process produces product meeting its 
predetermined specifications and quality attributes. So, manufacturing process of 
Metformin Hydrochloride and Glimepiride belayed tablet was considered as validated 
tablet. The three batches produce acceptable uniform results. 
 
 Manoj charde,S Jayani et al(2011)44- The purpose of formulation and evaluation of 
immediate release tablet of Metformin Hydrochloride on the basis of laboratory scale 
method. It prepared by the process of wet granulation method. To obtain the best 
optimized product from ten different formulations. The different types of excipients 
like disinitegrants, binders and lubricants are taken as variables. Mainly in this 
formulation contains PVPK-30 and also use PVPK-90.The physical properties and in 
vitro release profile showing the best comparable with reference product. The in vivo 
drug release can be checked and also carry the toxicity study. By making the 
combination with the some of new drugs the novel formulation can developed. 
 
 Villarroel stuart,Yclement et al(2015)45-This study about the comparing the 
dissolution profile of 7 batches of Metformin Hydrochloride formulations in 
simulated intestinal fluid. The dissolution test used to evaluate the pharmaceutical 
product performance. It includes the two products with trade name Glucophage in 
simulated intestinal fluid at ph 6.8.The dissolution were carried by paddle type 
apparatus used. It worked at 75 rpm in 900ml of simulated intestinal fluid at 
37±0.50c.1.25ml sample were removed at definite intervals of time of which 100µl 
diluted with the fresh medium. It is then analyzed by spectrophotometrically at 
233nm.The drug content between each of the formulations is 99% and 103%.And 
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formed six Metformin Hydrochloride formulations that fulfilled WHO requirements. 
The two innovator product with same trade name were similar biopharmaceutical 
quality but statistically different.  
 
 
 Pelango, Ramesh et al(2014)46-This study involved in comparative release analysis of 
commercial Metformin tablet .It involves the about five commercial brand were 
analyzed with their chemical content , drug release and physical characters .Randomly 
select the commercial brand of Metformin Hydrochloride selected and the groups 
were coded and analyzed. These tablets are analyzed by their shape, size, color, 
weight, friability, disinitegration, purity and drug content. All types of tests are done 
within product expiration dates. Purity determined by ultra violet spectro photometer 
.Based on the physical inspection Brand c500 is the smallest and Brand d500 is 
largest in size. All the brands had weight in loss less than 1% after the test of friability 
required content is present in brand AXL500 and brand d500.The sustained release 
drug dosage forms designed for maintain the therapeutic blood or tissue levels of 
drugs. 
 Madhusudhan Reddy et al(2013) 47-Formulation and evaluation of sustained release 
matrix tablets of Metformin Hydrochloride is prepared using Metformin, Xanthum 
gum, Gar gum, MCC, Magnesium state, PVP, IPA. It prepared by using of different 
proportion of the Xantham gum and Guar gum. The mostly natural excipents are 
having better sustaindility than marketed Metformin Hydrochloride tablet that 
prepared with the synthetic polymers. In this case the dissolution study proves that 
matrix tablet is shown 87.02%of drug release in 8hr where as marketed drug shown 
105.6% drug release in 8hr.  
 Kamoran Alam,Fraya zafar et al(2013)48- This study involved in the development 
and evaluation of Metformin Hydrochloride 500mg sustained release tablets. Two 
hydrophilic and hydrophobic formulations were formulated by the independent 
variables using the Dextrose ranged from 0-30% and plasdone S360 ranged from 19-
49%.The dissolution medium is used as a phosphate buffer pH6.8.Controlled release 
tablets are more preferred in the case of management of therapy due to its excellent 
compliance, decrease side effect and dose and the enhance safe use of high potency 
compounds. Results of this study indicated that all the formulations are under the first 
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order kinetics. The results of this study indicated that FHP1, batch1, and batch2 were 
found similar with reference formulation at pH 6.8. 
 Margret Chandria et al (2007)49- This study involved in the formulation and 
evaluation of extended release tablet of Metformin Hydrchloride tablet. The extended 
release Metformin tablet prepared by the wet granulation technique by using the 
different concentrations of polymers like Hydroxy propyl methyl cellulose and 
carbopol71G. The formulated tablet undergoes the pre compression study and the post 
compression study. The lubricating agent is used as Magnesium stearate. The punch 
size is using length19.7mm and 7.3mm width. The dissolution test is carried by using 
apparatus type2 paddle type using 6.8 phosphate buffers. F10 is matched with the 
innovator because it contains both HPMC K100 and carbopol 71G.  
 
 Ramteke K H et al(2012)50- The purpose of formulation of Metformin Hydrochloride 
in to beads, it gives the sustained release action of Metformin .This formulation is 
prepared by the ionotropic extended release technique. The calcium and aluminium is 
used as a cross linking agent. The beads prepared by the Das Mk. The alginate beads 
produce sustained release action about 10hr. 
 
 S M Moazzem Hossen et al(2014)51- The prime objective of this study is 
development of immediate release Metformin Hydrochloride tablet by using sodium 
starch glycolate, Collidon CL and Crosscarmellose sodium as super disintegrants. 
These are add in different concentrations 2-5%. Aerosol-200 is used to provide good 
flow property, Magnesium stearate as a lubricant. The formulations are evaluated for 
pre compression and post compression parameters. This study contains the effect of 
superdisintegrant agents. It concluded that high concentration of superdisintefrants 
produce high percentage release while lower concentration caused low release. 
 
 Narasimharan R et al(2011)52- This study involved the design and evaluation of 
Metformin Hydrochloride extended release tablets by direct compression method. 
Having an elimination half life of 5±2hrs and it maximum daily dose is 1000mg. The 
rate of drug release was in following order HPMC K15M>HPMC K100M>HPMC 
K200M. The drug release was faster in the formulation five due to HPMC K200.The 
wet granulation method was better choice to extend the drug release for 12hr. 
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5. DRUG AND EXCIPIENTS PROFILE.                                      
5.1 METFORMINE DRUG PROFILE (23) 
Figure no: 1 Structural formula 
 
Table no:2    Metformin drug profile 
 
 
 
 
                
PROPERTIES 
 
INFORMATION 
Molecular formula 
 
C4H11N5.HCl 
Molecular weight 
 
165.6 
IUPAC name 
 
N,N-Dimethylimidodicarbonimidic 
diamide 
Macroscopic appearance 
 
White crystalline powder 
Half life 
 
4-8.7hr 
Solubility 
 
Freely soluble as HCl salt 
pH 
 
6.68 
pKa 
 
12.4 
Use 
 
Oral hypoglycemic drug 
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Mechanism of action (19,20,21,22) 
 
Hypoglycemic 
 
 
                                   Metformin decrease hyperglycemia primarily by suppressing glucose 
production by the liver .The average person with type 2 diabetes has three times the normal 
rate of gluconeogenesis; Metformin treatment reduces this by over one third. The molecular 
mechanism of Metformin is incompletely understood: inhibition of mitochondrial respiratory 
chain, activation of AMP activated protein kinase(AMPK),inhibition of glucagon-induced 
elevation of  cAMP with reduced activation of protein kinase A, Inhibition of mitochondrial 
glycerophosphte dehydrogenase , and effect on gut microbiota have been proposed as 
potential mechanisms. 
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5.2 EXCIPIENTS PROFILE 
 GELATIN(24,25) 
 
Table no: 3   Gelatin excipient profile 
 
 
  
 
 
Empirical formula C6H12O6 
Sources Thermal denaturation of collagen , isolated  from animal 
skin and bones, also extracted from fish skins 
Description Light amber to faintly yellow, Transulcent flakes sheets. 
Brittle when dry 
Solubility Readily dissolves in hot water ,it also soluble in most polar 
solvents, 
Melting point The upper M.P is below human body temperature 
Viscosity Viscosity of gelatin/water mixture is greatest when the 
gelatin concentration is high and the mixture is kept cool at 
about 40C 
Loss on drying Not more than 16.0% 
Storage Store protected from moisture 
Application Gelling agent, suspending agent ,used in pharmaceuticals, 
photography and cosmetic manufacturing 
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SODIUM STARCH GLYCOLATE(33) 
 
Table no: 4  Sodium starch glycolate excipient profile 
 
 
                                                            
Non propriety names Explotab , Vivastar 
Synonyms Sodium salt of carboxy methyl ester of starch 
Empirical formula C2H5ONa 
Molecular weight 500000 - 11000000 
Description Weight to off white, Tasteless, Odorless, 
Relatively free flowing powder. 
Solubility Practically insoluble in organic solvents. It 
absorbs water rapidly. 
Functional categories Disintegrant, Dissolution aid, Suspending agent. 
Melting point 3380C 
Stability and Storage Store in well closed container to protect from 
humidity 
Incompatibilities Mostly compatible with all other tabulating 
ingredients. 
Applications Suspending and gelling agent 
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TALC(27) 
 
Table no: 5 Talc excipient profile 
 
 
 
Non proprietary names B.P- Purified talc 
Ph Eur-Talcum 
USP-Talc 
Synonyms At talc, Hydrous magnesium calcium silicate, 
Hydrous magnesium silicate, Magsil 
osmanthus, Soapstone 
Empirical formula Mg3Si4O10(OH)2 
Molecular weight 379.27 
Description Talc is very fine, white to grayish white, 
odorless, unctuous, crystalline powder. It 
adheres rapidly to the skin. 
Melting point 1500C 
Solubility Not soluble in water and slightly soluble in 
dilute mineral acids insoluble in water and 
ethanol. 
Functional categories Anti caking agent, Glidant, diluents and 
lubricants for tablets and capsules. 
Stability and storage conditions Talc is stable material and may be sterilized 
by heating at 1600C for not less than 1hr. 
Talc should stored in well closed container in 
a cool and dry place. 
Incompatibilities Incompatible with quaternary ammonium 
compound. 
Applications Lubricant, Diluents, Dissolution retardant in 
controlled release formulations. 
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METHYL PARABEN(28) 
 
Table no: 6  Methyl paraben excipient profile 
 
 
 
 
Non proprietary names Sodium methyl parahydroxy benzoate, 
Methyl paraben sodium salt. 
Synonyms Methyl 4-OH benzoate, Nipaginm 
Empirical formula C8H8O3 
Molecular weight 152.14732 
Description Soluble in water at 250C, slightly soluble 
in benzene, CCl4, ethanol. Ether, acetone, 
DMSO, methanol 
Melting point 125 -1280C 
Functional category Preservative 
Incompatibilities Incompatible with alkalis and metal salt 
Stability and storage conditions Stable at ambient temperature and under 
normal conditions of use dust may 
explosive. Keep container closed when not 
in use. 
Solubility Soluble in water at 250C, slightly soluble 
in benzene, CCl4, ether. 
Applications in pharmaceutical industry It is an antifungal agent, often used in 
variety of cosmetics and personal care 
products. It is used as food preservatives. 
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                                                           PROPYL PARABEN(29,37) 
                                                        
Table no: 7  Propyl paraben excipient profile 
 
 
 
 
 
 
Non proprietary names Propyis parahydroxy benzoate(Latin) 
Propyl 4-hydroxybenzoate(German) 
Propyl (Parahydroxy benzoate(French) 
Synonyms Propyl butex, Propyl chemosept, Propyl 4-
hydroxybenzoate,Parahydroxy benzoic acid 
propyl ester 
Empirical formula C10H12O3 
Molecular weight 180.2 
Description White crystalline powder,colourless crystals 
or white powder or chunky white solid 
odourless or faint aromatic odour,low toxicity 
and tastes. 
Solubility Water soluble 
Melting point 95-980C 
Stability and storage conditions Stable, stability maximum occurs at pH 4-5 
Functional categories Preservative, Food additive 
Incompatibility Incompatible with alkalies and metal salts 
Application in pharmaceutical industry An antimicrobial preservative in packaged 
foods, pharmaceuticals, cosmetics. 
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STARCH(26) 
 
Table no: 8   Starch excipient profile 
 
 
Non proprietary names Amylum, Polysacharide 
Synonyms Starch 1500,Starch LM 
Empirical formula (C6H10O5)n 
Molecular weight Depends on extend of gelatinization 
Description  odorless, tasteless 
Functional categories Thickening agent ,stiffening agent, gluing 
agent 
Solubility Insoluble in cold water or alcohol, become 
soluble on heating 
Stability and storage conditions Starch is stable and should be stored in a well 
closed container in a cool and dry place. 
Incompatibilities Incompatible with strong acids, alkali. Avoid 
mixing with strong oxidizing agent 
Applications Binder, Diluent, lubricant 
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6. METHODOLOGY 
 
6.1 PREFORMULATION STUDY(31) 
                                                Preformulation study is the investigation of physical and 
chemical properties of a drug substance alone and when combined with excipents. It is the 
first step in the rational development of dosage forms. The first learning phase is pre 
formulation. It involves reaching the goal of designing optimum drug delivery system by 
application of biopharmaceutical principles to physiochemical parameters. 
A)  Physical chemical evaluation of drug molecules 
 Description 
 Solubility 
 pH 
 Melting point 
 Chemical nature 
 Hygroscopicity 
 Loss on drying  
 Particle size determination 
 Flow property 
 
 
B) Compatibility study of drug and excipients 
 
 The information obtained from the preformulation studies 
indicates many of the subsequent events and approaches to be taken in to consideration 
during formulation development. 
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A) PHYSICO CHEMICAL PARAMETERS (32,33,34) 
 
1) Description 
 A detailed account of the certain or salient aspects, 
characteristics, or features of a subject matter or something seen, here or otherwise 
experienced or none. 
2) Solubility  
 Solubility is a chemical property referring to the ability for a 
given substance, the solute, to dissolve in a solvent. It is measured in terms of the maximum 
amount of solute dissolved in a solvent at equilibrium. 
  
3) pH 
It is the negative of the logarithm to base 10 of the concentration, measured in units of moles 
per liter of hydrogen ions. More precisely it is the negative of the logarithm to base 10 of the 
activity of the hydrogen ion. 
4) Melting point 
 A melting point is the temperature at which a solid substance 
assumes the liquid conditions. At the melting point solid and the liquid phase exist in 
equilibrium. The melting point of substance depends on pressure and is usually specified 
standard pressure. 
  
5) Chemical nature 
 Solubility, stability, bioavailability etc. of a substance depends 
on its chemical nature and this information helps to design a suitable dosage form. 
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6) Hygroscopicity 
                                 Hygroscopicity is the measurement of  a materials ability to absorb or 
release water as a function of humidity (i.e., water activity) The ideal way of hygroscopicity 
would be create a moisture sorption isotherm by looking at the changing water content vs. 
relative humidity and temperature. 
 
Table no: 9 Classification based on hygroscopic nature 
7) Loss on drying 
                                               This is widely used test method to determine the moisture 
content of the sample, although occasionally it may refer to the loss of any volatile matter 
from the sample. Therefore this method does not usually refer to the molecularly bound water 
or water of crystallization. 
 
8) Particle size determination 
 Particle size analysis is the collective name of the technical 
procedures or laboratory techniques, which determine the size range and or the average or 
mean size of the particles in a powder or liquid sample. It is an important method for research 
S.NO NATURE OF 
 SAMPLE 
RESULT OF THE DETERMINATION 
1 
 
Deliquescent Sufficient water absorbed to form a liquid 
2 
 
Very hygroscopic Increases in mass equal to or more than 15% 
3 
 
Hygroscopic Increases in mass less than 15% and equal to or more 
than 2% 
4 
 
Slightly hygroscopicity Increases in mass less than 2% and equal to or more than 
0.2% 
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in industrial development. The particle size of Metformin hydrochloride was done by sieving 
method. 
Sieve analysis 
Table no: 10 Classification based on %of sample retained or passed on test sieves . 
S.NO NATURE OF 
SAMPLE 
RESULT OF DETERMINATION 
1 Coarse powder NLT 95% of the sample mass pass through 14# and NMT 
40% pass through 36# 
2 Moderately coarse 
powder 
NLT 95% of the sample mass pass through 25# and NMT 
40% pass through 60# 
3 Moderately fine powder NLT 95% of the sample mass pass through 36# and NMT 
40% pass through 100% 
4 Fine powder NLT 95% of the sample mass pass through 100# and NMT 
40% pass through 150# 
5 Very fine powder NLT 95% of the sample mass through 150# and NMT 40% 
pass through 200# 
6 Super fine powder NLT 90% by number of particles are less than 10µm 
 
9) Flow property measurement: 
 It is a very important parameter to be measured, It affects the 
mass of uniformity of the dose .It is usually predicted in terms of angle of repose, bulk 
density, tapped density. 
Angle of Repose 
 The angle of repose of granular materials is the steepest angle 
of descent or dip relative to the horizontal plane o which a material can pile without 
slumbing. At this angle the material on the slope phase is on the verge of sliding 
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Where, 
Ө = Angle of repose 
h = Height 
r = Radius 
 A funnel fixed at a height approximately of 2-4 cm over the 
plat form. The loose powder slowly passed along the wall of funnel, till the cone of the 
powder formed. Determine the angle of repose by measuring the height of the cone of the 
powder and the radius of the heap of the powder. 
Table no: 11     Flow properties and the corresponding angle of repose 
 
Bulk Density (BD) and Tapped Density (TD) 
                                              Bulk density of a compound varies substantially with the method 
of crystallization, milling or formulation. When one considers the size of a high –dose 
S.NO FLOW PROPERTY ANGLE OF REPOSE(DEGREE) 
1 Excellent 25-30 
2 Good 31-35 
3 Fair 36-40 
4 Passable 41-45 
5 Poor 46-55 
6 Very poor 56-65 
7 Very Very poor >66 
               
           Ө = tan-1h/r 
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capsule product or the homogeneity of low dose formulations in which there are large 
difference in drug and the excipient densities. In addition to bulk density, it is frequently 
desirable to know the true density of a powder for computation of void volume or porosity of 
packed powder beds. 
 An accurately weighed quantity of the granules /powder was 
carefully poured into the graduated cylinder and volume was measured. Then the graduated 
cylinder was closed with lid and set into the tap density tester (USP). The density apparatus 
was set for 100 tap after that the volume was measured and continued operation till the two 
consecutive readings were equal. The bulk density and the tapped density were calculated 
using the following formulae.  
 
                
         
  
 
Compressibility index (CI) and Hausner ratio (HR) 
 The compressibility index and Hausner ratio methods are used 
for predicting powder flow characteristics. Both the compressibility index and the Hausner 
ratio were determined by using bulk density and the tapped density of a powder.  
 
 
  
      
            Bulk density = Weight of sample in gram / Volume occupied by the sample 
 
    Tapped density = Weight of sample in gram / Tapped volume 
 
C.I = Tapped – Untapped*100/ Tapped. 
 
H.R = Tapped density / Bulk density. 
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Table No: 12    Relation of flow property with Hausners ratio & compressibility index 
 
Compressibility index (%) Flow character Hausners ratio 
≤10 Excellent 1.00-1.11 
11-15 Good 1.12-1.18 
16-20 Fair 1.19-1.25 
21-25 Passable 1.26-1.34 
26-31 Poor 1.35-1.45 
32-37 Very poor 1.46-1.59 
>38 Very Very poor >1.60 
  
10)Moisture content : By Karl fisher method 
 Transfer the 35-40ml of methanol to the titration vessel and 
titrate with the reagent to the electrometric or visual end point to consume any moisture that 
may present. Weigh accurately 0.2-0.5gm of powdered sample, and quickly add to the 
titration vessel and perform the test potentiometrically. 
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6.2 MATERIALS AND EQUIPMENTS 
 
Table No: 13   List of materials for preparation of  Metformin 
 
 
 
 
 
 
 
 
S.NO Name of materials used 
 
Specifications Use 
1 Metformin 
 
IP Active ingredient 
2 Starch 
 
IP Diluent 
3 SFP 
 
IP Thickening agent 
4 Gelatin 
 
IP Thickening agent 
5 Methyl paraben 
 
IP Preservative 
6 Propyl paraben 
 
IP Preservative 
7 Talc 
 
IP Lubricant 
8 Sodium starch glycolate 
 
USP Super disintegrant 
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Table no: 14    List of equipments used for formulation of tablet 
 
  
S.NO EQUIPMENTS USED MANUFACTURER 
1 Electronic weighing balance Mettler , Switzerland 
2 Electronic weighing balance 1kg Averi India 
3 Max mixer Innofab India pvt.ltd,     
Hyderbad 
4 Fluidized bed dryer Alliance ,Bombay 
5 Cad mill Cadmach, Ahemmadabad 
6 Blender Bhuvaneswari, Madras 
7 Tablet Compresssion mechine 45 station double 
rotary 
Cadmach, Ahamedabad 
8 Electronic LOD measurement apparatus Sartorius, Germany 
9 Friability tester Veego ,Mumbai 
10 Tablet hardness tester Electrolb, Mumbai 
11 Bulk density apparatus Electrolab, Mumbai 
12 Dissolution apparatus USPII Veego, Mumbai 
13 Tablet Disintegration test apparatus Veego, Mumbai 
14 FT-IR Spectrophotometer Perkin Elmer,USA 
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6.3 PROCESS INVOVED IN TABLET PRODUCTION 
Figure No:2     Flow chart process involved in tablet production. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
                  Drug                  Excipient 
         Sieving and Weighing 
                 Dry Mixing 
              Wet granulation 
                      Drying 
                  Pulverization 
                      Lubrication 
                Compression 
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Steps involved in Formulation of Metformin granules 
Preparation of Raw materials:- 
 The raw materials and active pharmaceutical ingredients are 
weighed and sieving through the 22#mesh and check the weight of the raw materials. And 
they are collected in suitable baskets. 
Dry mixing:- 
 Check weight of the materials and sift pregelatinized starch 
through 40#mesh load in to mixer come granulation. Dry mix for 15min at low speed. 
Wet granulation: 
 Add binder solution to above powder which mixing for 5-15 
min in mixer at slow speed. Change mixer speed to fast and mix for 5-15 min till required 
end point achieved. If required add additional wet mass through mixer come granulator hole. 
Switch granulator at fast speed and mix for next 15 minute. And then pass through the cad 
mill to get required type of granules. And unload in to Fluidized bed dryer bowl, scrap 
material from cad mill bowl to Fluidized bed dryer bowl at end of batch. 
Drying: 
 Dry the wet milled granules in Fluidized bed dryer for 30minute 
and check for loss on drying for 30minute and rake again. Dry till loss on drying at not more 
than o.5%.Check loss on drying at 900C. 
Pulverization: 
 Pass the dried granules in to the cad mill. And add additional 
quantity of ingredients then, collect the good fractions of granules passing through the 
#14/150 mesh through metal detector loads the granules and get uniform sized granules. 
Lubrication: 
 All ingredients are lubricated by using the double cone blender 
and blend for 10minute at 6rpm. 
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6.4 Formulation Development Comparative data of various formulations of Metformin  
 
Trail-1 
Table No: 15    Formula of Metformin F1 
 
S.NO INGREDIENTS QUANTITY 
(mg) 
1 Metformin 500 
2 Starch 80 
3 Sodium Starch Glycolate - 
4 Talc 66.18 
5 Methyl Paraben 1.16 
6 Propyl Paraben 0.66 
7 Gelatin 2 
8 SFP QS 
9 Total 650 
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Trai-2 
 
Table no:16    Formula of Metformin F2 
 
 
 
S.NO INGREDIENTS QUANTITY 
(mg) 
1 Metformin 500 
2 Starch 85 
3 Sodium Starch Glycolate - 
4 Talc 61.18 
5 Methyl Paraben 1.16 
6 Propyl Praben 0.66 
7 Gelatin 2 
8 SFP QS 
9 Total 650 
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Trail -3 
 
Table No: 17    Formula of Metformin F3 
 
S.NO INGREDIENTS QUANTITY 
(mg) 
1 Metformin 500 
2 Starch 90 
3 Sodium Starch Glycolate - 
4 Talc 56.18 
5 Methyl Paraben 1.16 
6 Propyl Praben 0.66 
7 Gelatin 2 
8 SFP QS 
9 Total 650 
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Trail-4 
 
Table No: 18   Formula of Metformin F4 
 
S.NO INGREDIENTS QUANTITY 
(mg) 
1 Metformin 500 
2 Starch - 
3 Sodium Starch Glycolate 6.20 
4 Talc 139.98 
5 Methyl Paraben 1.16 
6 Propyl Paraben 0.66 
7 Gelatin 2 
8 SFP QS 
9 Total 650 
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Trail- 5 
 
Table No: 19     Formula of Metformin F5 
 
S.NO INGREDIENTS QUANTITY 
(mg) 
1 Metformin 500 
2 starch - 
3 Sodiun Starch Glycolate 6.25 
4 Talc 139.93 
5 Methyl Paraben 1.16 
6 Propyl Paraben 0.66 
7 Gelatin 2 
8 SFP QS 
9 Total 650 
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Trail No: 6 
 
Table No: 20    Formula of Metformin F6 
 
S.NO INGREDIENTS QUANTITY 
(mg) 
1 Metformin 500 
2 Starch - 
3 Sodium Starch Glycolate 6.20 
4 Talc 139.88 
5 Methyl Paraben 1.16 
6 Propyl Paraben 0.66 
7 Gelatin 2 
8 SFP QS 
9 Total 650 
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Trail – 7 
 
Table No: 21     Formula of Metformin F7 
 
 
 
S.NO INGREDIENTS QUANTITY 
(mg) 
1 Metformin 500 
2 Starch 80 
3 Sodium Starch Glycolate 6.25 
4 Talc 59.98 
5 Methyl Paraben 1.16 
6 Propyl Paraben 0.66 
7 Gelatin 2 
8 SFP QS 
9 Total 650 
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Trail No – 8 
 
Table No: 22      Formula of Metformin F8 
 
 
  
S.NO INGREDIENTS QUANTITY 
(mg) 
1 Metformin 500 
2 Starch 85 
3 Sodium Starch Glycolate 6.20 
4 Talc 54.93 
5 Methyl Paraben 1.16 
6 Propyl Paraben 0.66 
7 Gelatin 2 
8 SFP QS 
9 Total 650 
Methodology 
 
RVS College of Pharmaceutical Sciences Page 46 
 
 
 
Trail – 9 
 
Table No: 23    Formulation of Metformin F9 
 
S.NO INGREDIENTS QUANTITY 
(mg) 
1 Metformin 500 
2 Starch 90 
3 Sodium Starch Glycolate 6.25 
4 Talc 50.18 
5 Methyl Paraben 1.16 
6 Propyl Paraben 0.66 
7 Gelatin 2 
8 SFP QS 
9 Total 650 
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 COMPARATIVE DATA OF NINE FORMULATIONS OF METFORMIN (n=9)             
Table no: 24 Comparative data of nine formulations of Metformin 
 
 
 
 
 
 
 
 
 
 
 
 
 
INGREDIENTS F1 F2 F3 F4 F5 F6 F7 F8 F9 
Metformin 500 500 500 500 500 500 500 500 500 
Starch 80 85 90 - - - 80 85 90 
Sodium starch 
glycolate 
- - - 6.20 6.25 6.20 6.25 6.20 6.25 
Talc  66.18 61.18 56.18 139.98 130.93 139.88 59.98 54.93 50.18 
Methyl paraben 1.16 1.16 1.16 1.16 1.16 1.16 1.16 1.16 1.16 
Propyl paraben 0.66 0.66 0.66 0.66 0.66 0.66 0.66 0.66 0.66 
Gelatin 2 2 2 2 2 2 2 2 2 
SFP QS QS QS QS QS QS QS QS QS 
Total 650 650 650 650 650 650 650 650 650 
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6.5 COMPRESION OF TABLETS 
 
Compression parameters:-  
 The compression is done by using CADMACH 45 station                                                
compression machine specially designed for the compression of tablets having two different 
hoppers for the flow of granules. Two punches are setting in the compression machine for the 
compression of the tablets.  The pressure adjustment devises are used to adjust the pressure in 
the machine. It helps to adjust the weight of the tablet. The granules are passed through the 
two hoppers, and are filled in the die cavity and the final compression takes place with 
desired weight and the hardness being set. Due to the pressure on the upper and the lower 
punch the granules are compressed to get the tablet. 
Weight and the content uniformity of tablet are tested. 
 
Punch specification:- 
Upper punch: 6mm plain round with biweled edeges and kg embossed upper punch 
Lower punch: 6mm plain round with biweled edeges lower punch 
Temperature and relative humidity record 
Temperature: 25-260C 
Relative Humidity: 46-47% 
Compression parameter 
Description of tablet – White coloured , round, biweled edges and kg embossed. 
Weight of tablet - 650±5% 
Hardness – 8mm 
Friability – NMT 0.8% 
Disintegration time – NMT 15min 
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6.6 POST COMPRESSION PARAMETERS(38,39) 
 The quantitative evaluation and assessment of a tablets 
chemical, physical and bioavailability properties are important in the design of tablets and to 
monitor product quality. These properties are important since chemical breakdown or 
interaction between tablet components may alter the physical tablet properties, and greatly 
effect the bioavailability of the tablet system. There are various standards that have been set 
in the various pharmacopeias regarding the quality of pharmaceutical tablets. This includes 
the diameter, size, shape, thickness, weight, hardness, disintegration and dissolution 
characters. The diameter and the shape depend on the die and punches selected for the 
compression of tablets. The remaining specifications assure that tablets do not vary from one 
production lot to another. The following standards or quality control tests should be carried 
out on compressed tablets. 
 
1. General appearance 
                               The general appearance of tablets, visual identity and overall 
‘elegance’ is essential for consumer acceptance, control of lot-to-lot uniformity and general 
tablet uniformity and for monitoring the production process. The control of general 
appearance involves measurement of attributes such as a tablet’s size, shape, color, presence 
or absence of odour, taste, surface textures, physical flaws and consistency. 
 
2. Size and Shape 
                                             The type of tooling determines the shape and the dimensions of 
compressed tablets during the compression process. At a constant compressive load, tablets 
thickness varies with the changes in die fill, particles size distribution and packing of the 
powder mix being compressed and with tablet weight, while with a constant die fill, thickness 
varies with variation in compressive load. Tablet thickness is consistent from batch to batch 
or within a batch only if the tablet granulation or powder blend is adequately consistent in 
particle size and particle size distribution, if the punch tooling is of consistent length, and if 
the tablet press is clean and good working condition. 
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3. Thickness                                             
                                                  The thickness of individual tablet may be measured with a 
micrometer, which permits accurate measurements and provides information of the variation 
between the tablets. Tablet thickness should be control within a ±5% variation of a standard 
value. Any variations within a particular lot of tablets or between manufactures lots should 
not be apparent to the unaided eye for consumer acceptance of the products. In addition 
thickness must be controlled to facilitate packaging. The physical dimension of tablet along 
with the density of the material in the tablet formulation and their propotions, determine the 
weight of the tablet. The size and the shape of the tablet can also influence the choice of the 
tablet machine to use, the best particle size for granulation, production l ot size that can be 
made, the best type of tabletting processing that can be use, packaging operations and the cost 
of production.  
4. Weight variation 
                                             This test is also known as uniformity of weight. This does not 
apply to layer or enteric coated tablet. Weight of individual 20 tablets was noted and their 
mean weight was calculated, and the percentage deviation was calculated by using the 
formula. 
 
 
 Percentage deviation = X-X1 × 100 
   X 
Where, 
  X = actual weight of the tablet 
  X1= average weight of the tablet 
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5. Content uniformity 
 The content uniformity test is used to ensure that every tablet 
contain the amount of drug substance intended with little variation among tablet within a 
batch due to increased awareness of physiological availability. The content uniformity test 
has been included in the monograph of all coated and uncoated tablets and all capsules 
intended for oral administration where the ranges of size of the dosage form available include 
50mg or smaller sizes. Tablet monograph with a content uniformity requirements do not have 
weight variation requirements. For content uniformity test respective samples of 30 tablets 
are selected are 10 are assigned individually at least 9 must assay within 15% of the declared 
potency and none may exceed ± 25%. 
 
6. Friability 
 Friction and shock are the forces most often cause tablets to 
chip, cap or break. The friability test is closely related to tablet hardness and is designed to 
evaluate the abilility of the tablet to withstand abrasion in packaging, handling and shipping. 
It is usually measured by use of Roche fribilator. A number of tablets are weigh and placed in 
the apparatus their they are exposed to rolling and repeated shocks as they fall 6 inches in 
each turn within the apparatus. After 4 minute of this treatment of 100 revelations the tablets 
are weighing and the weight compared with the initial weight. The loss due to abrasion is a 
measure of the tablet friability. The values expressed as percentage a maximum weight loss 
of not more than 1% of the tablet being tested during the friability test is consider generally 
acceptable and any broken or smashed tablet are not picked up. Normally, when capping 
occurs friability values are not calculated. A thick tablet may have fewer tendencies to cap 
whereas thin tablets of large diameter often show expensive capping, thus indicate in that 
tablets with greater thickness have reduced internal stress.   
 
 
                                  Friability index = initial weight – final weight 
                                        Initial weight 
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7. Hardness 
                                      The resistance of tablet to capping, abrasion or breakage under 
conditions of storage, transportation and handling before usage depends on its hardness it 
now designated as either the Monsanto or stokes hardness tester .The instrument measure the 
force required to break the tablets when the force generated by a coil spring is applied 
diametrically to the tablet. 
                                                Hardness which is now more appropriately called crushing 
strength determinations are made during tablet production and are used to determine the need 
for pressure adjustment on tablet machine. If the tablet is too hard, it may not disintegrate in 
the required period of time to meet the dissolution specification; if it is too soft, it may not be 
able to withstand the handling during subsequent processing. Such as coating or packaging 
and shipping operation. The force required to break the tablet is measured in kilograms and 
crushing strength of 4kg usually consider to the minimum for satisfactory tablets. Oral tablet 
normally have the hardness 4- 10kg;However,hypodermic and chewable tablet are usually 
much softer(3 kg) and some sustained release tablet are much harder(10-20kg).Tablet 
hardness associated with other tablet properties such as densities and porosity. Hardness 
generally increases with normal storage of tablet and depends on the shape, chemical 
properties, binding agents and pressure applied during compression. 
 
8. Dissolution.(40) 
 Dissolution is the process by which a solid solute enters a 
solution. In the pharmaceutical industry it may be define as the amount of drug substance that 
goes in to solution per unit time under standardized conditions of liquid/solid interphase, 
temperature and solvent composition. 
                                             Dissolution behavior drug has a significant effect on 
pharmacological activity in fact a direct relationship between in vitro dissolution rate of many 
drugs and their solid dosage forms may or may not disintegrate when they interact with 
gastro intestinal fluid following oral administration depending on their design. 
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                     Dissolution kinetics is important in determining the 
bioavailability of a drug .A variety of designs of apparatus for dissolution testing have been 
proposed and tested, varying of simple beaker with stirrer to, complex system with lipid 
phases and lipid barrier where an attempt is made to mimic the biological milieu. The choice 
of apparatus to be used depends largely on the physiochemical properties of the dosage 
forms. 
The two types of methods are employed for performing the in vitro dissolution studies 
1. Basket type 
2. Paddle type 
Basket type 
                                      Basket method is used to evaluating the formulations that tend to float 
by carrying out the dissolution study. Plotting can be due to swelling of the formulation by 
taking some amount of dissolution medium. So, in this method the formulation is entrapped 
inside the basket that will not allow the formulation to float even if it swells and becomes 
lighter than the dissolution medium. 
Paddle type 
                                      Paddle method can be used for floating formulations and those 
formulations that don’t float even after swelling. The dissolution apparatus consists of a 
cylindrical vessel made of glass or inert transparent material. The volume of the vessel 
generally used was 900ml.In the vessel dissolution media was taken and the formulation to be 
evaluated had to be placed in it. A shaft is present which is connected at one end to a motor 
and the other end to a basket or paddle according to the method employed. 
                                          For basket method unless otherwise specified 40 mesh size for the 
basket was used. The rpm of the shaft was 100 rpm for basket method and 50 rpm for paddle 
method .In regular intervals of time samples were withdrawn from the vessel and analyzed 
for the drug release up to each interval by UV visible spectrophotometer. After withdrawing 
the sample it was replaced with same amount of dissolution medium to maintain sink 
conditions. 
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Dissolution of Metformin 
                                                                                                                                                                                          
Medium                        : 900ml of phosphate buffer pH 6.8 
RPM                             : 100 
Time                            : 0,5,10,15,30,45 
Apparatus                    : Paddle 
Temperature                : 37±0.50C 
Preparation of buffer pH 6.8 
Solution A:      M potassium dihydrogen phosphate      
6.8gm of potassium dihydrogen phosphate in 1000ml volumetric flask and dissolve in1000ml         
of purified water make up to volume with purified water. 
Solution B: 1M sodium hydroxide solution 
Weigh about 42gm sodium hydroxide pellets in 1000 ml volumetric flask and dissolve .Make 
up to volume with purified water 
 
Procedure 
Medium.  900ml of a0.68 percent w/v solution of potassium dihydrogen phosphate, adjusted 
to pH 6.8 by the addition of 1M sodium hydroxide, speed: 100 rpm 
Withdraw a suitable volume of the medium and filter , dilute suitably with water and measure 
the absorbance of the resulting solution at the maximum at about 233nm .Calculate the 
content of Metformin hydrochloride, in the medium taking. 806 as the specific absorbance at    
233nm. 
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Drug content(40) 
 The drug content of the metformin was found by the method of 
assay method. The drug content of the Metformin not less than 70% of the stated amount of 
Metformin hydrochloride.  
Procedure 
                    Weigh and powder 20 tablets of Metformin. Weigh a quantity 
of the powder containing about 0.1 g of Metformin Hydrochloride, shake with 70ml of water 
for 15minutes, dilute to 100.0ml with water and filter .Dilute 10.0ml of the filtrate to 100.0ml 
with water.Further dilute 10.0ml to 100.0ml with water and measure the absorbance of the 
resulting solution at the maximum at about 232nm.Calculate the content of Metformin 
Hydrochloride taking 798 as the specific absorbance at 232nm. 
 
Calculation 
 
 
 
        Percentage content of the sample 
                                             =Absorbance × 10×100 ×100×100×Average weight of the tablet        
                                              Specific absorbance ×Weight of one equivalent of tablet×10×10 
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Drug excipient compatibility study 
                                           Before making of formulation the drug and the excipients 
compatibility is very important. It is necessary to confirm that the drug does not react with 
the polymers and excipients under the experimental conditions and affect the product shelf 
life. 
Procedure 
                                           Drug and excipients are mixed with the different ratio. These 
mixtures were kept in 5ml white coloured vials. These vials are exposed to the room 
temperature and 400C/75%RH. 2-3gm of blend prepared which filled in 3 vials. Observations 
were made at zero weeks, 1 month, the samples were withdrawn for analysis of appearance, 
moisture content, assay and related substance. 
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7. RESULTS AND DISCUSSION 
 
7.1 PHYSIOCHEMICAL PARAMETERS 
1. DESCRIPTION 
 
Table no: 25  Description 
 
  
 
2. SOLUBILITY 
 
Table no: 26   Solubility 
 
RAW MATERIAL SOLUBILITY 
Metformin It is freely soluble in water and 95% alcohol and 
is practically insoluble in acetone, ether and 
chloroform. 
It also freely soluble as HCl salt. 
 
 
 
 
 
RAW MATERIAL COLOUR ODOUR TASTE 
Metformin White Odorless Tasteless 
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3. pH 
 
Table no:  27   pH 
 
RAW MATERIAL SOLUTION 
CONCENTRATION 
pH 
Metformin 1% aqueous solution of HCl 6.68 
 
 
 
4. MELTING POINT 
 
Table no:  28       Melting point 
 
RAW MATERIAL OBSERVED VALUE 
Metformin 2220 C    TO    2260 C 
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4.  CHEMICAL NATURE 
 
Table no:  29     Chemical nature of Metformin  
 
S.NO PARAMETERS METFORMIN 
1 Molecular formula C4H11N5.HCl 
2 Molecular weight 165.63 
3 IUPAC name 1,1-Dimethylbiguanide 
hydrochloride. 
4 Chemical nature Equimolar amounts of 
dimethylamine and 2-
cyanoguanidine are dissolved in 
toluene with cooling to make a 
concentrated solution, and an 
equimolar amount of hydrogen 
chloride is slowly added. The 
mixture begins to boil on its own, 
and after cooling, Metformin 
hydrochloride precipitates with a 
96% yield. 
 
5. HYGROSCOPICITY 
  
Table no: 30      Hygroscopic nature of Metformin 
 
RAW MATERIALS RESULT 
Metformin Hygroscopic 
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6. LOSS ON DRYING 
 
Table no: 31      Loss on drying 
 
RAW MATERIAL OBSERVED LOD 
Metformin Not more than 0.5% determined on 1.0g by 
drying in an oven at 1050 
 
 
7. SIEVE ANALYSIS 
 
Table no: 32      Sieve analysis 
 
RAW MATERIAL NATURE OF SAMPLE 
Metformin 100% pass through the 20#mesh 
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FLOW PROPERTY MEASUREMENT 
 
8. ANGLE OF REPOSE 
Table no: 33   Flow property and corresponding angle of repose 
 
RAW MATERIL (API) ANGLE OF REPOSE 
(DEGREES) 
FLOW PROPERTIES 
Metformin 33.69 Good 
 
9. DENSITY 
 
 BULK DENSITY 
 
Table no: 34    Bulk density 
 
RAW MATERIAL 
          (API) 
BULK DENSITY(PI)   
        (g/ml) 
Metformin 0.714 
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 TAPPED DENSITY 
 
Table no: 34   Tapped density 
 
RAW MATERIAL 
(API) 
TAPPED DENSITY (PI) 
(g/ml) 
Metformin 0.909 
 
 
 COMPRESSIBILITY INDEX 
 
 Table no: 36  compressibility index 
 
RAW MATERIAL 
(API) 
COMPRESSIBILITY 
INDEX (%) 
FLOW PROPERTY 
Metformin 21.45 Passable 
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 HAUSNER RATIO 
 
Table no:  37  Hausner’s ratio 
 
RAW MATERIAL 
          
       (API) 
HAUSNER RATIO FLOW PROPERTY 
Metformin 1.27 Passable 
 
 
10. DRUG CONTENT 
 
Table no: 38   Drug content 
 
RAW MATERIAL 
(API) 
ASSAY 
 (%) 
Metformin It contains not less than 98.5% and not more 
than 101.0% of C4H11N5.HCl 
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7.2 COMPATIBILITY STUDIES 
 
Table no: 39  Compatibility study of Metformin with excipients 
DRUG EXCIPIENTS 1stDAY 1stWEEK 2ndWEEK 3rdweek 
400C&75% 
     RH 
400C&75% 
       RH 
400C&75% 
       RH 
400C&75% 
       RH 
M STARCH ND ND ND ND 
M GELATIN ND ND ND ND 
M METHYL 
PARABEN 
ND ND ND ND 
M PROPYL 
PARABEN 
ND ND ND ND 
M SFP ND ND ND ND 
M TALC ND ND ND ND 
M SODIUM 
STARCH 
GLYCLOLATE 
ND ND ND ND 
 
 
Where, 
             M=Metformin 
             RH=Relative humidity 
            ND=Change not detectable 
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Figure no; 3 FTIR spectra of pure Metformin tablet. 
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Figure no: 4 FTIR spectrum of optimized formulation. 
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7.3 PRECOMPRESSION PARAMETERS OF METFORMIN TABLETS 
Table No: 40  Pre compression parameter of Metformin granules trials: 
 
Formulations Bulk 
density 
(gm/cm2) 
Tapped 
density 
(gm/cm2) 
C.I (%) Angle of 
repose(0) 
H.R Moisture 
content 
F1
 
 
 
0.72 0.90 20.0 350.41’ 1.25 0.0213 
F2
 
 
 
0.702 0.93 23.22 370.95’ 1.32 0.0235 
F3
 
 
 
0.714 0.95 24.84 420.23’ 1.2 0.026 
F4
 
 
 
0.710 0.83 14.45 450.72’ 1.16 0.0231 
F5
 
 
 
0.68 0.79 13.92 380.95’ 1.16 0.0245 
F6
 
 
 
0.57 0.67 14.92 430.55 1.17 0.022 
F7
 
 
 
0.59 0.68 13.23 310.63’ 0.09 0.219 
F8 
 
 
0.710 0.82 13.41 320.23’ 1.15 0.274 
F9
 
 
 
0.8 0.912 12.28 330.69 1.14 0.274 
 
Inference: Formulations F1  to F3 has  showing  the  significant  flowproperty,angle of repose 
and hausner’s ratio because of  the absence of sodium starch glycolate and inclusion of 
starch.and in case of F4-F6 has indicating the high angle of repose due to the poor flow 
property in the absence of starch.F7-f9 shown good flow as indicating the less angle of repose  
because of  increase in concencentration of lubricant Sodium starch glycolate and starch also.  
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7.4 POST COMPRESSION PARAMETER OF METFORMIN TABLETS  
Table No: 41  Post compression parameter of Metformin tablets 
Formulations Weight 
variations 
(mg) 
Hardness 
(kg/cm2) 
 
 
Thickness 
(mm) 
Disintegration 
Time(min) 
Friability 
    (%) 
 
F1 
 
 
630-684 
 
8 
 
3.64 
 
7 
 
0.05 
 
F2 
 
 
625-691 
 
7 
 
3.93 
 
9 
 
0.06 
 
F3 
 
 
609-674 
 
8 
 
4.82 
 
8 
 
0.07 
 
F4 
 
 
622-688 
 
5 
 
4.56 
 
9 
 
0.08 
 
F5 
 
 
623-689 
 
9 
 
3.52 
 
8 
 
0.06 
 
F6 
 
 
610-674 
 
12 
 
3.29 
 
7 
 
0.07 
 
F7 
 
 
612-676 
 
14 
 
4.86 
 
7 
 
0.05 
 
F8
 
 
 
626-691 
 
9 
 
3.46 
 
8 
 
0.07 
 
F9
 
 
 
621-687 
 
8 
 
4.56 
 
8 
 
0.06 
 
Innovator 
(Glucophage) 
 
550-600 
 
11 
 
3 
 
9 
 
0.04 
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7.5 DRUG CONTENT  
 Table No: 42 Drug Content Values of Metformin                   
FORMULATION METFORMIN 
F6
 
88.53 
            F7
 
95.43 
F8
 
96.64 
F9
 
96.44 
 
Calculation of drug content value of Metformin  
 
        Percentage content of the sample 
                                             =Absorbance × 10×100 ×100×100×Average weight of the tablet        
                                              Specific absorbance ×Weight of one equivalent of tablet×10×10 
 
 
Example:-  weight of 20 Metformin Hydrochloride tablets =12.723g 
 Average weight = 0.63615g 
 Weight of one equivalent sample =0.12653g 
 Specific absorbance  =798 
 Absorbance factor   =7654 
Percentage content of the sample =  
 
 7654×10×100×100×100×0.6315 
 = 
 798×0.12653×10×10 
                                       = 96.445% 
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7.6 DRUG RELEASE 
7.6.1. INNOVATOR DRUG RELEASE PROFILE 
Table No: 43 Innovator drug release profile 
Time Metformin(Innovator) 
0 0 
5 68.05 
10 79.45 
15 85.87 
30 96.57 
45 99.89 
Figure no: 5  Release profile of innovator 
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7.6.2 DRUG RELEASE VALUE OF METFORMIN 
 
Table No: 44  Percentage Drug release value of Metformin 
 
FORMULATIONS 
 
 
% drug release of Metformin at 
45minutes 
 
F1 
 
78.42% 
 
F2 
 
84.76% 
 
F3 
 
82.96% 
 
F4 
 
89.43% 
 
F5
 
 
 
83.07% 
 
F6
 
 
 
95.42% 
 
F7 
 
 
93.09% 
 
F8
 
 
 
96.68% 
 
F9
 
 
 
98.85% 
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7.6.3 RELEASE PROFILE OF METFORMIN IN F6 COMPARED WITH 
INNOVATOR 
Table No: 45 comparative release of Metformin from innovator and F6
 
 
 
 
 
 
 
 
 
 
Figure No: 6  Release profile of Metformin in F6 compared with innovator 
 
 
Inference:The release profile of the Metformin from F6 was less than compared to innovator 
at the end of 45 minutes 
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0 
 
0 
 
0 
 
5 
 
68.05 
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7.6.4 RELEASE PROFILE OF METFORMIN IN F7
 
COMPARED WITH 
INNOVATOR 
Table No: 46  Comparative release of Metformin from innovator and F7  
Time(min) 
 
% Release of innovator % Release from F7
 
 
0 
 
0 
 
0 
 
5 
 
68.05 
 
65.45 
 
10 
 
79.45 
 
75.43 
 
15 
 
85.87 
 
87.54 
 
30 
 
96.57 
 
90.42 
 
45 
 
99.89 
 
93.09 
 
Figure No. 7 Release profile of Metformin in F7
 
compared with innovator 
 
 
 
 
Inference:  The release profile of Metformin from F7 was compared to innovator and the 
release rate was less than the innovator at the end of 45 minutes 
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7.6.5 RELEASE PROFILE OF METFORMIN IN F8
 
COMPARED WITH  
 THE INNOVATOR 
Table No: 47 Comparitive release of Metformin from innovator and F8
 
Time(min) 
 
% Release of innovator %Release from F8
 
 
0 
 
0 
 
0 
 
5 
 
68.05 
 
66.53 
 
10 
 
79.45 
 
77.82 
 
15 
 
85.87 
 
85.42 
 
30 
 
96.57 
 
92.53 
 
45 
 
99.89 
 
96.68 
 
Figure No.8 Release profile of Metformin in F8 compared with the innovator 
 
 
 
Inference: The release profile of Metformin from F8
 
was compared with the innovator and 
the release was compatible to that of innovator at the end of 45 minute. 
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7.6.6 RELEASE PROFILE OF METFORMIN FROM F9
 
COMPARED WITH 
INNOVATOR  
Table No: 48 Comparative release of Metformin from innovator and F9  
Time(min) 
 
%Release of innovator % Release from F9
 
 
0 
 
0 
 
0 
 
5 
 
68.05 
 
65.54 
 
10 
 
79.45 
 
80.57 
 
15 
 
85.87 
 
84.32 
 
30 
 
96.57 
 
93.05 
 
45 
 
99.89 
 
98.85 
 
Figure No.9 Release profile of Metformin from F9
 
compared with innovator 
 
 
Inference: The release profile of Metformin from the F9 was compared with the innovator 
and the release was almost equal and compatible with innovator at the end of 45 minutes. 
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7.6.7 COMPARISON OF DISSOLUTION PROFILE OF FORMULATIONS WITH 
INNOVATOR 
Table No: 49  Comparison of dissolution profile of Metformin formulations with innovator  
Time 
(min) 
Innovator                        
                           % Drug Release 
F6 F7 F8 F9 
 
5 
 
 
68.05 
 
58.93 
 
65.45 
 
66.53 
 
65.54 
 
10 
 
 
79.45 
 
72.63 
 
75.43 
 
77.82 
 
80.57 
 
15 
 
 
85.87 
 
84.32 
 
87.54 
 
85.42 
 
84.32 
 
30 
 
 
96.57 
 
89.95 
 
90.42 
 
92.53 
 
93.05 
 
45 
 
 
99.89 
 
95.42 
 
93.09 
 
96.68 
 
98.85 
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7.6.8 COMPARITIVE RELEASE PROFILE OF METFORMIN IN VARIOUS 
FORMULATIONS WITH INNOVATOR 
 
Figure No: 10 Comparitive release profile of Metformin in various formulations with 
innovator 
 
 
 
 
Inference: Comparitive release profile of Metformin from various formulations showing the 
release from the F9 matching with the innovator 
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7.7 STABILITY STUDY 
7.7.1 STABILITY DATAS FOR OPTIMIZED FORMULATIONS AT 250C&60%RH 
FOR METFORMIN IMMEDIATE RELEASE TABLET 
Table No: 50  Stability data for optimized formulations at 250C & 60% RH for Metformin 
immediate release tablet IP 
S.NO PARAMETERS STORAGE CONDITIONS (250 C& 60% RH) 
 
INITIAL  
 
30 DAYS 45 DAYS 
1 
 
Description 
 
 
Weight coloured 
,round shaped 
N.D N.D 
2 Weight variation 
 
 
645-655 Within limits Within 
limits 
3 Hardness 
 
 
5 5.2 5 
4 Thickness 
 
 
4.9 4.9 4.9 
5 Friability 
 
 
0.32 0.34 0.33 
6 Disintegration time 
 
 
8 8 9 
7 Drug release 
 
 
99.88 99.88 99.87 
8 Drug content 
 
 
650 650 649 
9 Moisture content 
 
 
0.0216 0.0219 0.0321 
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7.7.2 STABILITY DATA FOR OPTIMIZED FORMULATIONS AT 400C &75%RH 
FOR METFORMIN IMMEDIATE RELEASE TABLET 
Table No: 51  Stability data for optimized formulations at 400C & 75% RH for Metformin 
immediate release tablet IP 
S.NO PARAMETERS STORAGE CONDITIONS (400 C& 75% RH) 
 
INITIAL  
 
30 DAYS 45 DAYS 
1 
 
Description 
 
 
weight colored 
,round shaped 
N.D N.D 
2 Weight variation 
 
 
645-655 Within limits Within 
limits 
3 Hardness 
 
 
5.3 5.2 5.2 
4 Thickness 
 
 
4.56 4.5 4.5 
5 Friability 
 
 
0.32 0.33 0.33 
6 Disintegration time 
 
 
9 8 8 
7 Drug release 
 
 
99.83 99.83% 99.8% 
8 Drug content 
 
 
650.39 650.05 649.95 
9 Moisture content 
 
 
0.0216 0.0219 0.0231 
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Table No: 52 Drug release of Metformin at 250C & 60% RH  
DRUG                                  % Drug release 
 
Initial 
 
30 days   45 days 
Metformin 99.88 
 
99.88 99.87 
 
 
Figure No: 11 Drug release of Metformin at 250c&60%RH 
 
 
 
Inference:The drug release was not significantly reduced at the end of 30 days and 45 days 
storage at 250c &60%RH indicating stability of the formulation. All parameters are within the 
specified limits at the end of the storage. 
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Table No: 53 Drug release of Metformin at 400C & 75% RH  
DRUG                                  % Drug release 
 
Initial 
 
30 days   45 days 
Metformin 99.83 
 
99.83 99.8 
 
 
Figure No. 12 Drug release of Metformin at 400C & 75% RH 
 
 
 
Inference: The drug release was not significantly reduced at the end of 30 days and 45 days 
storage at 400c &75%RH indicating stability of the formulation. All parameters are within the 
specified limits at the end of the storage. 
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SUMMARY AND CONCLUSION 
 The present study was aimed at developing, evaluating and optimization of the 
oral hypoglycaemic drug Metformin 
Totally 9 formulations are prepared by using different ratios of Metformin ,Starch ,Gelatin ,Talc 
,Methyl paraben sodium, Propyl paraben sodium and Sodium starch glycolate. Each 9 
formulations contain the twenty tablets. The granules are prepared separately in a Max mixer. 
                    Pre compression parameters like Bulk density, True density, Angle of repose 
indicate all the formulations are showing flow properties. The tablets are compressed by double 
rotary compression machine and tablets are evaluated for post compression parameters like 
weight variation, Hardness, Friability, Disintegration and Dissolution parameters. 
 Formulations F1-F3 sodium starch glycolate is not used, in that formulations 
starch is used in definite proportions. F4-F6 sodium starch glycolate is used and the starch is not 
use in this formulations. Sodium starch glycolate and starch used in case of F7-F9. These 
formulations can be compared to innovator. In the formulation of F9 is more matched to the 
innovator (Metformin) according to the drug release profile. A good result is getting by using 
both sodium starch glycolate and starch. The F9 formulation contains Metformin- 500mg, starch-
90mg, Sodium Starch Glycolte-6.25mg, Talc-50.18, Methyl Paraben-1.16, Propyl Paraben-
0.66mg, Gelatin-2mg. 
 The compressed tablets are subjected to stability studies at 400C and 
75%RH, 250C and 60%RH. Samples were analyzed at regular intervals as mentioned in stability 
protocol. 
 From the study, it may be concluded that formulation F9 (it contains both 
sodium starch glycolate and starch in suitable proportions) can be prepared as immediate release 
formulation compared to conventional formulation. 
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